FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Susanne Saussele

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Germany

Co-author Network

Publications

TOP 3
Kristina Ihrig; Norbert Marschner; Ralph Naumann; Christoph Röllig; Susanne Saussele; Hans Tesch; Birgit Fath; Michael Fuchs; Michael Hallek; Nicola Gökbuget
[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].
Fabio Efficace; Ute Kossak-Roth; Franco Mandelli; Adel Naeem; Ourania Nicolatou-Galitis; Susanne Saussele; Michele Baccarani; Massimo Breccia; Giovanni Caocci; Annarita Cardoni; Weichu Chie; Kim Cocks; Marco Vignetti; Mirjam Sprangers
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Daniel Nowak; Verena Nowak; Julia Oblaender; Seishi Ogawa; Andreas Reiter; Susanne Saussele; Brigitte Schlegelberger; Wolfgang Seifarth; Christel Weiss; Jan Braess; Thomas Buechner; Philipp Erben; Alice Fabarius; Claudia Haferlach; Benjamin Hanfstein; Anna Hecht; Wolf-Karsten Hofmann; Gero Hütter; Marion Klaumuenzer; Alexander Kohlmann; Maximilian Mossner; Martin C Müller; Florian Nolte; Eva Lengfelder
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Susanne Saussele (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kristina Ihrig; Norbert Marschner; Ralph Naumann; Christoph Röllig; Susanne Saussele; Hans Tesch; Birgit Fath; Michael Fuchs; Michael Hallek; Nicola Gökbuget
[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].
Onkologie 2013;36 Suppl 2():23-8.
2012: Fabio Efficace; Ute Kossak-Roth; Franco Mandelli; Adel Naeem; Ourania Nicolatou-Galitis; Susanne Saussele; Michele Baccarani; Massimo Breccia; Giovanni Caocci; Annarita Cardoni; Weichu Chie; Kim Cocks; Marco Vignetti; Mirjam Sprangers
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Annals of hematology 2012;91(9):1371-81.
2012: Daniel Nowak; Verena Nowak; Julia Oblaender; Seishi Ogawa; Andreas Reiter; Susanne Saussele; Brigitte Schlegelberger; Wolfgang Seifarth; Christel Weiss; Jan Braess; Thomas Buechner; Philipp Erben; Alice Fabarius; Claudia Haferlach; Benjamin Hanfstein; Anna Hecht; Wolf-Karsten Hofmann; Gero Hütter; Marion Klaumuenzer; Alexander Kohlmann; Maximilian Mossner; Martin C Müller; Florian Nolte; Eva Lengfelder
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.
Genes, chromosomes & cancer 2012;51(8):756-67.
2012: Joëlle Guilhot; Michele Baccarani; Francisco Cervantes; Richard E Clark; François Guilhot; Andreas Hochhaus; Sergei Kulikov; Jiri Mayer; Andreas L Petzer; Gianantonio Rosti; Philippe Rousselot; Giuseppe Saglio; Susanne Saussele; Bengt Simonsson; Juan-Luis Steegmann; Andrey Zaritskey; Rüdiger Hehlmann
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood 2012;119(25):5963-71.
2012: Susanne Saussele; Markus Pfirrmann
Clinical trials in chronic myeloid leukemia.
Current hematologic malignancy reports 2012;7(2):109-15.
2012: Verena Hoffmann; Doris Lindoerfer; Gert Ossenkoppele; Markus Pfirrmann; Kimmo Porkka; Gianantonio Rosti; Susanne Saussele; Bengt Simonsson; Michele Baccarani; François Guilhot; Joelle Guilhot; Joerg Hasford; Rüdiger Hehlmann
The EUTOS CML score aims to support clinical decision-making.
Blood 2012;119(12):2966-7.
2011: Markus Pfirrmann; Susanne Saussele; Rüdiger Hehlmann; Andreas Hochhaus; M Lauseker; Joerg Hasford
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
Leukemia 2011;25(9):1433-8.
2011: Joerg Hasford; Michele Baccarani; François Guilhot; Joelle Guilhot; Verena Hoffmann; Doris Lindoerfer; Gert Ossenkoppele; Markus Pfirrmann; Kimmo Porkka; Gianantonio Rosti; Susanne Saussele; Bengt Simonsson; Rudiger Hehlmann
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Blood 2011;118(3):686-92.
2011: Rüdiger Hehlmann; Andreas Hochhaus; Dieter K Hossfeld; Susanne Jung-Munkwitz; Stefan W Krause; Michael Lauseker; Armin Leitner; Martin C Müller; Christoph Nerl; Markus Pfirrmann; Nadine Pletsch; Hans Pralle; Ulrike Proetel; Leopold Balleisen; Alois Gratwohl; Claudia Haferlach; Mathias Hänel; Joerg Hasford; Brigitte Schlegelberger; Susanne Saussele
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):1634-42.
2011: Rüdiger Hehlmann; Susanne Jung-Munkwitz; Susanne Saussele
Treatment of chronic myeloid leukemia when imatinib fails.
Expert opinion on pharmacotherapy 2011;12(2):269-83.
2010: Christoph Walz; David Grimwade; Susanne Saussele; Eva Lengfelder; Claudia Haferlach; Susanne Schnittger; Marina Lafage-Pochitaloff; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.
Genes, chromosomes & cancer 2010;49(5):471-9.
2010: Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Blood 2010;115(10):1880-5.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2006: Susanne Saussele; K Adam; Andreas Hochhaus; marie bene; Thomas Büchner; A Burnett; G Finazzi; Christa Fonatsch; E Gluckman; Nicola Gökbuget; David Grimwade; Torsten Haferlach; M Hallek; Joerg Hasford; Dieter Hoelzer; P Ljungman; Dietger Niederwieser; Hubert Serve; B Simonsson; T J de Witte; Rüdiger Hehlmann
[Clinical research at the European LeukemiaNet].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Susanne Saussele; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla; Rüdiger Hehlmann
[Clinical research within the German competence net "acute and chronic leukemias"].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(5):414-20.
2005: Eva Lengfelder; Susanne Saussele; Andreas Weisser; Thomas Büchner; Rüdiger Hehlmann
Treatment concepts of acute promyelocytic leukemia.
Critical reviews in oncology/hematology 2005;56(2):261-74.
2005: Senta Ulrike Gnad-Vogt; Ralf-Dieter Hofheinz; Susanne Saussele; Sebastian Kreil; Andreas Willer; Frank Willeke; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Anti-cancer drugs 2005;16(4):435-40.
2005: Ralf-Dieter Hofheinz; Ulrike Gnad-Vogt; Axel Wein; Susanne Saussele; Sebastian Kreil; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Anti-cancer drugs 2005;16(1):39-45.
2004: Ralf-Dieter Hofheinz; Jörg Thomas Hartmann; Andreas Willer; Karin Oechsle; Gernot Hartung; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Carsten Bokemeyer; Rüdiger Hehlmann; Andreas Hochhaus
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
British journal of cancer 2004;91(5):834-8.
2004: Ralf-Dieter Hofheinz; Andreas Willer; Andreas Weisser; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Jörg Thomas Hartmann; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
British journal of cancer 2004;90(10):1893-7.
2004: Eva Lengfelder; Andreas Reiter; Susanne Saussele; Andreas Weisser; Rüdiger Hehlmann
Monitoring of minimal residual disease in acute promyelocytic leukemia.
Annals of hematology 2004;83 Suppl 1():S79-80.
2003: Andreas Reiter; Susanne Saussele; David Grimwade; Joseph L Wiemels; Mark Segal; Marina Lafage-Pochitaloff; Christoph Walz; Andreas Weisser; Andreas Hochhaus; Andreas Willer; Anja Reichert; Thomas Büchner; Eva Lengfelder; Rüdiger Hehlmann; Nicholas C P Cross
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
2000: Susanne Saussele; Andreas Weisser; Martin C Müller; M Emgi; Paul La Rosée; Peter Paschka; C Kuhn; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia 2000;14(11):2006-10.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Andreas Hochhaus; Andreas Weisser; Paul La Rosée; Michael Emig; Martin C Müller; Susanne Saussele; Andreas Reiter; C Kuhn; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia 2000;14(6):998-1005.
2000: Andreas Hochhaus; Andreas Reiter; Susanne Saussele; Anja Reichert; Michael Emig; J Kaeda; Beate Schultheis; Ute Berger; P C Shepherd; N C Allan; Rüdiger Hehlmann; J M Goldman; Nicholas C P Cross
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Blood 2000;95(1):62-6.
1999: Michael Emig; Susanne Saussele; H Wittor; Andreas Weisser; Andreas Reiter; Andreas Willer; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Hochhaus
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia 1999;13(11):1825-32.
1998: A Krämer; Andreas Hochhaus; Susanne Saussele; Anja Reichert; Andreas Willer; Rüdiger Hehlmann
Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.
Leukemia 1998;12(6):893-8.
1998: Andreas Hochhaus; Andreas Reiter; H Skladny; Anja Reichert; Susanne Saussele; Rüdiger Hehlmann
Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;144():36-45.
1997: Andreas Willer; Susanne Saussele; W Gimbel; Wolfgang Seifarth; P Kister; Christine Leib-Mösch; Rüdiger Hehlmann
Two groups of endogenous MMTV related retroviral env transcripts expressed in human tissues.
Virus genes 1997;15(2):123-33.
1994: Rüdiger Hehlmann; P Kister; Andreas Willer; M Simon; M Schenk; Wolfgang Seifarth; G Papakonstantinou; Susanne Saussele; Hans-Jochem Kolb; H Ansari
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Leukemia 1994;8 Suppl 1():S127-32.